Literature DB >> 2121042

Immunocytochemical detection of kappa and lambda light chain V region subgroups in human B-cell malignancies.

A Solomon1, D T Weiss, S D Macy, R A Antonucci.   

Abstract

We have used a sensitive immunoperoxidase method and highly specific anti-light chain antisera to determine the light chain variable region (VL) subgroup nature of cytoplasmic (c) and cell surface (s) Ig expressed by human monoclonal plasma cells and B lymphocytes. The immunocytochemical characterization of cIg and sIg used antisera specific for the established kappa light chain V kappa subgroups (V kappa I, V kappa II, V kappa III, and V kappa IV) and the lambda light chain V lambda subgroups (V lambda I, V lambda II/V, V lambda IV, and V lambda VI). Studies were performed using cytospin preparations of bone marrow-, peripheral blood-, and lymph node-derived cells from patients with multiple myeloma, amyloidosis AL, and Waldenström's macroglobulinemia and with low-, mid-, and high-grade B-cell malignancies. The V kappa or V lambda subgroup of the cIg or sIg also could be identified after deparaffinization and enzyme treatment of formalin-fixed, paraffin-embedded specimens. For those patients who had monoclonal serum or urinary Igs, there was complete concordance between the VL subgroup of the secreted Ig and that of the cIg or sIg. The percentage distribution of V kappa or V lambda subgroups on the sIg of cells from patients with chronic lymphocytic leukemia (CLL) and other cytomorphologic types of B-cell malignancies differed from that found for kappa- or lambda-type Bence Jones proteins obtained from patients with multiple myeloma, amyloidosis AL, and Waldenström's macroglobulinemia. In contrast to the plasma cell and lymphocytoid plasma cell diseases, a relative predominance of certain VL subgroups, ie, V kappa IV, V lambda III, and V lambda IV, and the absence of the amyloid-associated V lambda VI subgroup were found in CLL and related diseases. The immunocytochemical techniques used make possible a rapid means to demonstrate B-cell monoclonality and provide further evidence for the selective expression of certain VL genes in human B-cell neoplasia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121042      PMCID: PMC1877536     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  28 in total

Review 1.  The CD5 B cell.

Authors:  T J Kipps
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

Review 2.  Cold agglutination. Antibodies and antigens.

Authors:  D Roelcke
Journal:  Clin Immunol Immunopathol       Date:  1974-01

3.  Bence Jones proteins and light chains of immunoglobulins. IV. Immunochemical differentiation among proteins within each of the three established kappa-chain classes.

Authors:  A Solomon; C L McLaughlin
Journal:  J Immunol       Date:  1971-01       Impact factor: 5.422

4.  Preferential association of kappa IIIb light chains with monoclonal human IgM kappa autoantibodies.

Authors:  D K Ledford; F Goñi; M Pizzolato; E C Franklin; A Solomon; B Frangione
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

5.  Bence Jones proteins and light chains of immunoglobulins. Preferential association of the V lambda VI subgroup of human light chains with amyloidosis AL (lambda).

Authors:  A Solomon; B Frangione; E C Franklin
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

6.  Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin.

Authors:  I Royston; J A Majda; S M Baird; B L Meserve; J C Griffiths
Journal:  J Immunol       Date:  1980-08       Impact factor: 5.422

7.  A common idiotope on human rheumatoid factors identified by a hybridoma antibody.

Authors:  D A Carson; S Fong
Journal:  Mol Immunol       Date:  1983-10       Impact factor: 4.407

8.  Sequence similarities among kappa IIIb chains of monoclonal human IgM kappa autoantibodies.

Authors:  B Pons-Estel; F Goñi; A Solomon; B Frangione
Journal:  J Exp Med       Date:  1984-09-01       Impact factor: 14.307

9.  Similarities in the light chains of anti-gamma-globulins showing cross-idiotypic specificities.

Authors:  H G Kunkel; R J Winchester; F G Joslin; J D Capra
Journal:  J Exp Med       Date:  1974-01-01       Impact factor: 14.307

10.  Identification of a p69,71 complex expressed on human T cells sharing determinants with B-type chronic lymphatic leukemic cells.

Authors:  C Y Wang; R A Good; P Ammirati; G Dymbort; R L Evans
Journal:  J Exp Med       Date:  1980-06-01       Impact factor: 14.307

View more
  6 in total

1.  Development and evaluation of agents for targeting visceral amyloid.

Authors:  Jonathan S Wall; Alan Solomon; Stephen J Kennel
Journal:  Tijdschr Nucl Geneeskd       Date:  2011-12

Review 2.  Structural and functional properties of human lambda-light-chain variable-region subgroups.

Authors:  A Solomon; D T Weiss
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

3.  Transgenic mouse model of AA amyloidosis.

Authors:  A Solomon; D T Weiss; M Schell; R Hrncic; C L Murphy; J Wall; M D McGavin; H J Pan; G W Kabalka; M J Paulus
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

4.  Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies.

Authors:  Sandra Davern; Lian X Tang; Teresa K Williams; Sallie D Macy; Jonathan S Wall; Deborah T Weiss; Alan Solomon
Journal:  Am J Clin Pathol       Date:  2008-11       Impact factor: 2.493

5.  Induction in mice of human light-chain-associated amyloidosis.

Authors:  A Solomon; D T Weiss; M B Pepys
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

6.  Splenic plasma cells can serve as a source of amyloidogenic light chains.

Authors:  Alan Solomon; Sallie D Macy; Craig Wooliver; Deborah T Weiss; Per Westermark
Journal:  Blood       Date:  2008-12-02       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.